Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

A New Vitamin D Analog, 2MD, Restores Trabecular and Cortical Bone Mass and Strength in Ovariectomized Rats With Established Osteopenia

A New Vitamin D Analog, 2MD, Restores Trabecular and Cortical Bone Mass and Strength in... An orally active, highly potent analog of 1α,25‐dihydroxyvitamin D3, 2MD, restores trabecular and cortical bone mass and strength by stimulating periosteal bone formation and decreasing trabecular bone resorption in OVX rats with established osteopenia.Introduction: The purposes of this study were to determine the effects of long‐term treatment with 2‐methylene‐19‐nor‐(20S)‐1α,25(OH)2D3 (2MD) on restoring bone mass and bone strength in ovariectomized (OVX) rats with established osteopenia and 2MD effects on bone formation and bone resorption on trabecular and cortical bone surfaces.Materials and Methods: Sprague‐Dawley female rats were sham‐operated (sham) or OVX at 4 months of age. Beginning at 8 weeks after OVX, OVX rats were orally dosed with 2MD at 0.5, 1, 2.5, 5, or 10 ng/kg/day for 16 weeks. Serum calcium was measured at 6, 13, and 16 weeks after treatment, and bone mass and structure, bone formation, bone resorption, and bone strength were determined at the end of the study.Results: Serum calcium did not change significantly with 2MD at 0.5 or 1 ng/kg/day, whereas it significantly increased at 2.5, 5, or 10 ng/kg/day. 2MD significantly and dose‐dependently increased total body BMD, total BMC, and stiffness of femoral shaft (FS), maximal load and stiffness of femoral neck, and toughness of the fifth lumbar vertebral body (L5) at all doses compared with OVX controls. In 2MD‐treated OVX rats, there was a dose‐dependent increase in total BMD and total BMC of the distal femoral metaphysis (DFM), trabecular bone volume of L3, ultimate strength and stiffness of L5, and maximal load of FS compared with OVX controls at dosages ≥1 ng/kg/day. At dosages >2.5 ng/kg/day, most of the bone mass and bone strength related parameters were significantly higher in 2MD‐treated OVX rats compared with sham controls. Bone histomorphometric analysis of L3 showed dose‐dependent decreases in osteoclast number and osteoclast surface on trabecular bone surface and a dose‐dependent increase in periosteal bone formation associated with 2MD treatment.Conclusions: 2MD not only restored both trabecular and cortical bone mass but also added bone to the osteopenic OVX rats beyond that of sham controls by stimulating bone formation on the periosteal surface and decreasing bone resorption on the trabecular surface. 2MD increased bone mass and strength at doses that did not induced hypercalcemia. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Bone and Mineral Research Oxford University Press

A New Vitamin D Analog, 2MD, Restores Trabecular and Cortical Bone Mass and Strength in Ovariectomized Rats With Established Osteopenia

Download PDF
14 pages

Loading next page...
 
/lp/oxford-university-press/a-new-vitamin-d-analog-2md-restores-trabecular-and-cortical-bone-mass-gprYSmUsQM

References (57)

Publisher
Oxford University Press
Copyright
Copyright © 2005 ASBMR
ISSN
0884-0431
eISSN
1523-4681
DOI
10.1359/jbmr.050605
Publisher site
See Article on Publisher Site

Abstract

An orally active, highly potent analog of 1α,25‐dihydroxyvitamin D3, 2MD, restores trabecular and cortical bone mass and strength by stimulating periosteal bone formation and decreasing trabecular bone resorption in OVX rats with established osteopenia.Introduction: The purposes of this study were to determine the effects of long‐term treatment with 2‐methylene‐19‐nor‐(20S)‐1α,25(OH)2D3 (2MD) on restoring bone mass and bone strength in ovariectomized (OVX) rats with established osteopenia and 2MD effects on bone formation and bone resorption on trabecular and cortical bone surfaces.Materials and Methods: Sprague‐Dawley female rats were sham‐operated (sham) or OVX at 4 months of age. Beginning at 8 weeks after OVX, OVX rats were orally dosed with 2MD at 0.5, 1, 2.5, 5, or 10 ng/kg/day for 16 weeks. Serum calcium was measured at 6, 13, and 16 weeks after treatment, and bone mass and structure, bone formation, bone resorption, and bone strength were determined at the end of the study.Results: Serum calcium did not change significantly with 2MD at 0.5 or 1 ng/kg/day, whereas it significantly increased at 2.5, 5, or 10 ng/kg/day. 2MD significantly and dose‐dependently increased total body BMD, total BMC, and stiffness of femoral shaft (FS), maximal load and stiffness of femoral neck, and toughness of the fifth lumbar vertebral body (L5) at all doses compared with OVX controls. In 2MD‐treated OVX rats, there was a dose‐dependent increase in total BMD and total BMC of the distal femoral metaphysis (DFM), trabecular bone volume of L3, ultimate strength and stiffness of L5, and maximal load of FS compared with OVX controls at dosages ≥1 ng/kg/day. At dosages >2.5 ng/kg/day, most of the bone mass and bone strength related parameters were significantly higher in 2MD‐treated OVX rats compared with sham controls. Bone histomorphometric analysis of L3 showed dose‐dependent decreases in osteoclast number and osteoclast surface on trabecular bone surface and a dose‐dependent increase in periosteal bone formation associated with 2MD treatment.Conclusions: 2MD not only restored both trabecular and cortical bone mass but also added bone to the osteopenic OVX rats beyond that of sham controls by stimulating bone formation on the periosteal surface and decreasing bone resorption on the trabecular surface. 2MD increased bone mass and strength at doses that did not induced hypercalcemia.

Journal

Journal of Bone and Mineral Research – Oxford University Press

Published: Dec 4, 2009

Keywords: osteoporosis; 2‐methylene‐19‐nor‐(20S)‐1α,25(OH) 2 D 3; bone strength; bone formation; biomechanics; 1,25‐dihydroxyvitamin D 3

There are no references for this article.